Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
September 05, 2017 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the...
Editas Medicine Announces Second Quarter 2017 Results and Update
August 09, 2017 16:03 ET
|
Editas Medicine
Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration ...
Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
August 07, 2017 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine to Participate in Investor Conferences in June
June 13, 2017 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine Names Andrew Hirsch to Board of Directors
May 31, 2017 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors,...
Editas Medicine Announces First Quarter 2017 Results and Update
May 15, 2017 16:01 ET
|
Editas Medicine
Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye diseases Completed successful follow-on...
Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
May 13, 2017 11:05 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first...
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
May 11, 2017 09:15 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC)...
Editas Medicine to Present at Investor Conferences in May
May 08, 2017 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
May 08, 2017 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...